
Opinion|Videos|March 31, 2025
Results and Takeaways From a 12-month Claims Analysis of Ruxolitinib
Author(s)Gary M. Owens, MD , Lawrence Eichenfield, MD
Panelists discuss how ruxolitinib cream demonstrated significant clinical efficacy in treating atopic dermatitis over a 12-month period, with claims analysis revealing improved disease control, reduced rescue medication use, fewer dermatology visits, and a favorable safety profile compared to standard treatments, supporting its role as a valuable non-steroidal topical option for long-term management.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
The biosimilars market is projected to nearly double — here's where the growth is coming from
2
Journavx helped most patients avoid opioids after surgery, a recent study found
3
Endometriosis increases the risk of Type 2 diabetes
4
Cholinergic urticaria: Hives caused by heat and what can be done about it
5














